Ignota Labs, a Cambridge, UK-based AI-driven drug turnaround company, has closed a $6.9 million in seed funding round.
Investors
The round was co-led by Montage Ventures and AIX Ventures, with additional participation from Modi Ventures, Blue Wire Capital, and Gaingels.
Montage Ventures is an early-stage venture capital firm founded in 2013 and based in Menlo Park, California, back ambitious founders leveraging state-of-the-art technology to improve consumers' lives. The firm focuses on investing in companies within the fintech, consumer products and services, and life sciences & healthcare sectors.
AIX Ventures is an AI-focused, early-stage venture firm founded by Shaun Johnson and Richard Socher. AIX Ventures partners with visionary entrepreneurs and some of the world's leading AI practitioners. Founded in 2021, the firm invests across the AI landscape, focusing on the future of work, biotech, healthcare, and dev tools. AIX Ventures is based in the San Francisco Bay Area.
Ignota Labs Use of Funds
This funding will be used to expand Ignota Labs' pipeline by acquiring additional distressed assets and advancing into early-stage clinical trials of their first asset, a PDE9A inhibitor.
About Ignota Labs
Founded by Sam Windsor, Jordan Lane, and Layla Hosseini-Gerami, Ignota Labs focuses on rescuing promising drugs abandoned due to safety concerns, enabling these therapies to be revived and brought to market. The company uses AI to help improve the safety of drugs and accelerate drug discovery processes. Its AI platform, SAFEPATH, combines deep learning, cheminformatics, and bioinformatics to analyze biological data, identify safety issues, and predict drug toxicity.
Funding Details
Company: Ignota Labs
Raised: $6.9M
Round: Seed
Funding Date: February 2025
Lead Investors: Montage Ventures, AIX Ventures
Additional Investors: Modi Ventures, Blue Wire Capital, Gaingels
Company Website: https://www.ignotalabs.ai/
Software Category: AI-driven Drug Development, Drug Safety, Drug Discovery
Source: Connor Mitchell